October 4, 2024 10:08 AM EDT
News Briefing

Ed­i­tas sells fu­ture CRISPR li­cense fees; Plus, news about On­colyt­ics Biotech

ENDPOINTS

Ed­i­tas sells fu­ture CRISPR li­cens­ing fees from Ver­tex: DRI Health­care Trust is pay­ing $57 mil­lion up­front to the gene edit­ing com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

Af­ter $14B ex­it, Karuna co-founder finds next bet; Ex-Re­genxbio CEO Ken Mills heads to Tag­works

Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

Ex­clu­sive: Re­lay Ther­a­peu­tics cuts an­oth­er 10% of com­pa­ny, cit­ing con­tin­ued stream­lin­ing ef­forts

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times